Back to results
US 2022/0054623 A1Published application
Modification of engineered influenza hemagglutinin polypeptides
AssigneeSanofi Pasteur Limited
InventorsTod Strugnell, Eliud Oloo, Raymond Oomen
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.
Claims20
1-102. (canceled)
A method of immunizing a subject against seasonal and pandemic influenza virus, comprising administering to the subject a pharmaceutical composition comprising a recombinant influenza hemagglutinin (HA) polypeptide, wherein the recombinant influenza HA polypeptide comprises:
- an engineered head region derived from an engineered influenza HA polypeptide with a predominantly seasonal immune profile;
- and
- a stem region derived from a pandemic strain.
Dependencies are inferred from the claim text.